Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
AstraZeneca
Medtronic
Harvard Business School
Baxter

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

CLINDESSE Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Clindesse, and when can generic versions of Clindesse launch?

Clindesse is a drug marketed by Perrigo Pharma Intl and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-four patent family members in twenty-one countries.

The generic ingredient in CLINDESSE is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.

Drug patent expirations by year for CLINDESSE
Drug Prices for CLINDESSE

See drug prices for CLINDESSE

Drug Sales Revenue Trends for CLINDESSE

See drug sales revenues for CLINDESSE

Recent Clinical Trials for CLINDESSE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Watson Laboratories, Inc.Phase 3
Actavis Inc.Phase 3

See all CLINDESSE clinical trials

Recent Litigation for CLINDESSE

Identify potential future generic entrants

District Court Litigation
Case NameDate
Perrigo Pharma International D.A.C. v. Actavis Laboratories UT Inc.2015-04-02

See all CLINDESSE litigation

Pharmacology for CLINDESSE
Synonyms for CLINDESSE
(2S-trans)-Methyl 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-L-threo-.alpha.-D-galacto-octopyranoside 2-(dihydrogen phosphate)
[(2R,3R,4S,5R,6R)-6-[(1S,2S)-2-chloro-1-[[(2S,4R)-1-methyl-4-propyl-pyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyl-tetrahydropyran-3-yl] dihydrogen phosphate
[(2R,3R,4S,5R,6R)-6-[(1S,2S)-2-chloro-1-[[(2S,4R)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate
[(2R,3R,4S,5R,6R)-6-[(1S,2S)-2-chloro-1-{[(2S,4R)-1-methyl-4-propylpyrrolidin-2-yl]formamido}propyl]-4,5-dihydroxy-2-(methylsulfanyl)oxan-3-yl]oxyphosphonic acid
24729-96-2
7(S)-Chloro-7-deoxylincomycin 2-phosphate
AB01566857_01
AC1L9EKE
AKOS008901431
API0002056
AS-12554
AX8019646
BDBM241975
BRD-K27771035-001-02-5
C11728
C18H34ClN2O8PS
CAS-24729-96-2
CHEMBL3184512
Cleocin phosphate
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Cleocin T
Clinda-Derm
Clindagel
Clindamax
Clindamycin (phosphate)
Clindamycin 2-dihydrogen phosphate
Clindamycin 2-phosphate
Clindamycin dihydrogenphosphat
Clindamycin injection
Clindamycin phosphate
Clindamycin phosphate (JP17/USP)
Clindamycin phosphate [USAN:JAN]
Clindamycin phosphate [USAN:USP:JAN]
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Clindamycin-2-dihydrogenphosphat
CLINDAMYCIN-2-PHOSPHATE
Clindets
CS-4620
D01073
Dalacin P
Dalacin T
Dalacin-S (TN)
DSSTox_CID_28603
DSSTox_GSID_48677
DSSTox_RID_82873
DTXSID1048677
EH6D7113I8
EINECS 246-433-0
Evoclin (TN)
HY-B1064
L-threo-alpha-D-galacto-Octapyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-
L-threo-alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-
LS-98133
Methyl (2S-trans)-7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-L-threo-alpha-D-galacto-octopyranoside, 2-(dihydrogen phosphate)
Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2- pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside 2-(dihydrogen phosphate)
Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside 2-(dihydrogen phosphate)
MFCD07793328
MolPort-015-163-859
NCGC00163494-01
NCGC00166320-01
NCGC00386379-01
PubChem5913
s2048
SCHEMBL37148
SR-01000872581
SR-01000872581-1
ST24046358
Tox21_113055
Tox21_113410
U 28508
U-28,508
U-28508
UFUVLHLTWXBHGZ-MGZQPHGTSA-N
UNII-EH6D7113I8
ZINC4102185

US Patents and Regulatory Information for CLINDESSE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo Pharma Intl CLINDESSE clindamycin phosphate CREAM;VAGINAL 050793-001 Nov 30, 2004 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Perrigo Pharma Intl CLINDESSE clindamycin phosphate CREAM;VAGINAL 050793-001 Nov 30, 2004 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CLINDESSE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Perrigo Pharma Intl CLINDESSE clindamycin phosphate CREAM;VAGINAL 050793-001 Nov 30, 2004   Start Trial   Start Trial
Perrigo Pharma Intl CLINDESSE clindamycin phosphate CREAM;VAGINAL 050793-001 Nov 30, 2004   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for CLINDESSE
Drugname Dosage Strength RLD Date
➤ Subscribe Vaginal Cream 2% ➤ Subscribe   Start Trial

Supplementary Protection Certificates for CLINDESSE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1304992 CR 2013 00053 Denmark   Start Trial PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
1304992 SPC/GB13/061 United Kingdom   Start Trial PRODUCT NAME: CLINDAMYCIN PHOSPHATE IN COMBINATION WITH TRETINOIN.; REGISTERED: IE PA1332/043/001 20130322; UK PL15142/0249 20130624
1304992 2013/044 Ireland   Start Trial PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Baxter
Colorcon
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.